MAIA Biotechnology (NYSEAMERICAN:MAIA) Releases Earnings Results

MAIA Biotechnology (NYSEAMERICAN:MAIA) issued its quarterly earnings data on Tuesday. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.21, Zacks reports.

MAIA Biotechnology Stock Performance

NYSEAMERICAN MAIA traded down $0.21 on Thursday, reaching $2.18. 129,215 shares of the company were exchanged, compared to its average volume of 286,302. The firm has a market capitalization of $52.12 million, a P/E ratio of -1.57 and a beta of 0.32. MAIA Biotechnology has a fifty-two week low of $0.82 and a fifty-two week high of $5.99.

Insider Activity at MAIA Biotechnology

In other MAIA Biotechnology news, Director Cristian Luput bought 22,133 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The stock was purchased at an average price of $2.51 per share, for a total transaction of $55,553.83. Following the completion of the purchase, the director now directly owns 389,483 shares in the company, valued at $977,602.33. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 36.98% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.